Klotho Neurosciences (KLTO) said Tuesday it is collaborating with AAVnerGene on adeno-associated virus manufacturing and targeted tissue delivery for its therapies to treat Alzheimer's, Parkinson's, ALS, and other conditions.
The collaboration will concentrate on producing KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and other motor neuron disorders, and KLTO-303 for aging-related conditions, the company said.
"The two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes," said Klotho CEO Joseph Sinkule.
Financial terms of the collaboration were not disclosed.
Price: 1.19, Change: -0.01, Percent Change: -0.83
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.